OC1 3 U 500K STENT & TRADE

Sheet 1

Ì,

PTO/SB/08A (08-03)

Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

collection of information unless it contains a valid OMB control number. Paperwork Reduction Act of 1995, no persons are required to respond to a Complete if Known Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

of 4

Application Number 10/764,201 Filing Date 1/23/2004 First Named Inventor Eakle, et al. Art Unit 1633 **Examiner Name** Leavitt Attorney Docket Number **IOGEN-08729**

Examiner Initials*	Cite No.1	Document Number Number-Kind Code ^{2 (f known)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
ML	1	^{US-} 5,871,958	02/16/1999	Cullen	Whole Document
ML	2	^{US-} 6,162,898	12/19/2000	Cullen	Whole Document
		US-			
		US-		1977	
· · · -		US-			
		US-			
		US-	1		
		US-			<u> </u>
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages		
		Country Code ² Number ⁴ 'Kind Code ³ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°	
ML	3	EP 0406557	05/23/1990	Bachmayer et al	Whole Document		
	<u> </u>						
	1					l	

	W. W. Z		
Examiner Signature	/Maria Leavitt/	Date Considered	11/15/2006

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. *Applicant's unique citation designation number (optional). *See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. *Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). *For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. *Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. *Applicant is to place a check mark here if English language

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (08-03)
Approved for use through 07/31/2008. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
a collection of information unless it contains a valid OMB control over the control of the control over the cont

Substitu	Substitute for form 1449/PTO			Complete if Known		
Q	10 10 10 11 14 14 14			Application Number	10/764,201	
INF	ORMATIC	ON DIS	CLOSURE	Filing Date	1/23/2004	
STA	TEMEN	T BY A	PPLICANT	First Named Inventor	Eakle, et al.	
	(Use es meny			Art Unit	1633	
	(Use es man)	y sneets as i	iecessary)	Examiner Name	Leavitt	
Sheet	2	of	4	Attorney Docket Number	IOGEN-08729	

	1 20	NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
ML	4	Pollari, F.L., et al., "Effects of bovine leukemia virus infection on production and reproduction in dairy cattle," Can. J. Vet. Res., 56(4):289-95 (1992)	
	5	Hidaka et al., "Post-transcriptional regulator (rex) of HTLV-1 initiates expression of viral structural proteins but suppresses expression of regulatory proteins," EMBO J 7:519 (1988)	
	6	Malim, M.H., et al., "Immunodeficiency virus rev trans-activator modulates the expression of the viral regulatory genes," Nature, 335:181 (1988)	
	7	Rimsky, L., et al., "Functional replacement of the HIV-1 rev protein by the HTLV-1 rex protein," Nature, 335:738 (1988)	
	8	Green, P.L., et al., The Retroviridae, p. 227-311, vol. 3, Eds. Levy, J.A., Plenum Press, New York, N.Y., (1994)	
	9	Ghysdael, K., et al., "Bovine leukemia virus," Current Topics in Microbiology and Immunology 112:1 (1984) Gree, P.L., et al., The Retroviridae, p. 227-311, vol. 3, Eds. Levy, J.A., Plenum Press, New York, N.Y., (1994)	
	10	Orlik, O., and Splitter G.A., "Progression to persistent lymphocytosis and tumor development in bovine leukemia virus (BLV)-infected cattle correlates with impaired proliferation of CD4+ T cells in response to gag- and envenceded BLV proteins," J. Virol., 70(11):7584 (1996)	
	11	Elovaara, I., et al., "High human T cell lymphotropic virus type 1 (HTLV-1)-specific precursor cytotoxic T lymphocyte frequencies in patients with HTLV-1-associated neurological disease," J. Exp. Med., 177:1567 (1993)	
	12	Lassauzet, ML, et al., "Factors associated with transmission of bovine leukemia virus by contact in cows on a California dairy," Amer. J. Epidemiol, 133:164-76 (1991)	
$\overline{\Psi}$	13	Lassauzet, M.L., et al., "Effect of brucellosis vaccination and dehorning on transmission of bovine leukemia virus in heifers on a California dairy," Can. J. Vet. Res. 54:184-189 (1990)	

Examiner /Maria Leavitt/	Date Considered	11/15/2006
--------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

considered. Include copy of this form with next communication to applicants to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The Information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

PTC/S8/08B (08-03) Approved for use through 07/31/2008, OMB 0651-0031

	1 Abranca on man amanga and 1	
	U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE	:
Under the Paperwork Reduction Act of 1995, no persons are	required to respond to a collection of information unless it contains a valid OMB control number.	•
	Complete if Vacuus	•

	Substitute for form 1449/PTO			Complete if Known		
				Application Number	10/764,201	
INF	ORMATION	DIS	CLOSURE	Filing Date	1/23/2004	
STA	TEMENT B	BY A	PPLICANT	First Named Inventor	Eakle, et al.	
	(ilea ao many sho	ata an a		Art Unit	1633	
(Use as many sheets as necessary)			ocessery)	Examiner Name	Leavitt	
Sheet	3	of	4	Attorney Docket Number	IOGEN-08729	

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
ML L	14	Buxton, B.A., and Schultz, R.D., "Factors affecting the infectivity of lymphocytes from cattle with bovine leukosis virus," Can. J. Comp. Med., 48(4):365-369 (1984)	
	15	Herskowitz, I., Nature 329:317 (1987)	
	16	Hope, I.A., and Struhl, K., "Functional dissection of a eukaryotic transcriptional activator protein, GCN4 of yeast," Cell 46:885 (1986)	
	17	Gentz, R., et al., "Parallel association of Fos and Jun leucine zippers juxtaposes DNA binding domains," Science 243:1695 (1989)	
	18	Triezenberg, S.J., et al., Gen. & Devel., 2:718 (1988)	
	19	Friedman A.D., et al., "Functional dissection of VP16, the trans-activator of herpes simplex virus immediate early gene expression," Nature, 335:452 (1988)	
	20	Wachsman, V., et al., "HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes," Science 235:674 (1987)	
,	21	Green, M., et al., "Mutational analysis of HIV-1 Tat minimal domain peptides: identification of trans-dominant mutants that suppress HIV-LTR-driven gene expression," Cell 58:215 (1989)	
	22	Trono, D., et al., "HIV-1 Gag mutants can dominantly interfere with the replication of the wild-type virus," Cell 59:113 (1989)	
$\overline{\mathbf{V}}$	23	Orlik, O., and Splitter G.A., "Optimization of lymphocyte proliferation assay for cells with high spontaneous proliferation in vitro: CD4+ T cell proliferation in bovine leukemia virus infected animals with persistent lymphocytosis," J. Immunol. Methods 199:159 (1996)	

Examiner /Maria Leavitt/	Date Considered	11/15/2006
----------------------------	--------------------	------------

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant:

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (08-03) Approved for use through 07/31/2006. OMB 0651-0031

	U.S. Patent and Trademark Office; U.S. C	EPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respon	other if explain adjustmential unless it contains	ne a valid OMB control aumber

Substitu	te for form 1449/PTO			Complete if Known		
				Application Number	10/764,201	
INF	ORMATION	DIS	CLOSURE	Filing Date	1/23/2004	
STA	ATEMENT E	BY A	PPLICANT	First Named Inventor	Eakle, et al.	
	(Use as many she	ote se r	ocasean/l	Art Unit	1633	
(and an individual of the control of				Examiner Name	Leavitt	
Sheet	4	of	4	Attorney Docket Number	IOGEN-08729	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	minist I and I mende name of the details (in or it this EET TENO), this of the distinct (which appropriate), the		of e T²	
ML	24	Kimata, J.J., et al., "The mitogenic activity of human T-cell leukemia virus type I is T-cell associated and requires the CD2/LFA-3 activation pathway," J. Virol., 67:3134 (1993)		
	25	Boris-Lawrie et al., "In vivo study of genetically simplified bovine leukemia virus derivatives that lack tax and rex," J Virol 71(2):1514-20 (1997)		
\forall	26	Gatei M.H., et al., "Experimental infection of sheep with bovine leukemia virus: infectivity of blood, nasal and saliva secretions," Zentralbl Veterinarmed, (B) 36(9):652-60 (1989)		

Examiner		Date	
0'	/Maria Leavitt/	54.0	11/15/2006
Signature	/	Considered	11/13/2000

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 605. Uraw line through citation in not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.